Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of COVID-19 Convalescent Plasma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Blood donors:~1. Age: \>18 and \<60 years~2. Body weight : \>55 kg~3. Confirmed previous SARS CoV-2 infection~4. Minimum 28 days after the last symptom or finishing of the isolation, or~5. 21 day without symptoms from the date of the negative SARS CoV-2 test~6. Written informed consent to participate in this clinical trial, to donate plasma and to store the specimen for future testing.~7. Concentration of COVID-19 IgG antibodies more than 5 AU/ml (Because measurement of neutralizing antibody titers is not available now, storing of retention sample from the convalescent plasma donation is performed for determining antibody titers at a later date)~8. Male donors, or female donors who have not been pregnant, or female donors who have been pregnant tested negative for HLA antibodies~9. Individuals who meet all regular voluntary donor eligibility requirements~Patients/recipients:~1. Age: \>18 years~2. Admitted to an acute care facility for the treatment of COVID-19 complications~3. Patients with severe or immediately life-threatening COVID-19, or~4. Patients who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.~5. Informed consent provided by the patient or healthcare proxy~Exclusion Criteria:~Blood donors:~1. Age : \<18 or \>60 years~2. Female subjects who are pregnant~3. HIV1,2 hepatitis B,C or syphilis infection~4. Donors ineligible for regular voluntary blood donation~Patients/recipients:~1. Age : \<18 years~2. Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products)~3. Patients who received in the past 30 days immunoglobulin therapy~4. Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Hospitalized patients with SARS CoV-2 infection (Type: OTHER): Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).